
    
      This study was planned to recruit 52 transfusion-dependent Î²-thalassemia patients with severe
      cardiac iron overload. However only 13 patients participated in the study during a 3 year and
      5 month timeframe. The study was terminated due to the slow enrollment rate due to scarcity
      of the patient population with severe cardiac iron overload.
    
  